Laboratory of Gastroenterology, St. Luc University Hospital, Université catholique de Louvain, Brussels, Belgium.
Mol Carcinog. 2012 Oct;51(10):816-25. doi: 10.1002/mc.20849. Epub 2011 Aug 31.
Activation of Ras and its downstream signaling pathways, likely contribute to the development of hepatocarcinoma. We have previously shown that intraperitoneal injections of the Ras inhibitor S-trans, trans-farnesylthiosalicyclic acid (FTS) blocks Ras activation and prevents heptocarcinoma development in rats receiving weekly injections of the carcinogene diethylnitrosamine (DEN) for 16 wk. Using this in vivo model, we evaluated the relationship between the tumor preventive effect of Ras inhibition and activation of downstream signaling pathways, cell proliferation, cell cycle events, and angiogenesis. Western blotting, quantitative PCR, immunohistochemistry, and transcription factor activity assays were used. DEN-induced activation of NFkB and Stat3 was abrogated by FTS treatment. FTS treatment showed no effect on DEN-induced elevation of TNFα, interleukin 6 and TLR4, known activators of these transcription factors. FTS significantly reduced phosphorylation of the MAPkinase p38 and of the p70S6 kinase, a surrogate marker for mTor activation, without affecting ERK and AKT phosphorylation. These events were associated with reduced c-myc and cyclin D expression as well as reduced cell proliferation in transformed, GSTp-positive hepatocytes. Moreover, FTS treatment shifted cell proliferation from transformed hepatocytes to apparently normal, GSTp negative hepatocytes. FTS treatment did not down-regulate expression of angiogenesis markers HIFα, VEGF, VEGF receptor1, and placenta growth factor. FTS treatment inhibits important signaling pathways involved in cellular proliferation leading to strongly reduced proliferation of transformed hepatocytes without affecting normal hepatocytes. This re-adjustment of the proliferation balance likely contributes to the tumor preventive of FTS in the context of Ras inhibition in hepatocarcinogenesis.
Ras 的激活及其下游信号通路的激活可能有助于肝癌的发展。我们之前已经表明,腹腔内注射 Ras 抑制剂 S-反式,反式-法呢基硫代水杨酸(FTS)可阻断 Ras 的激活,并阻止接受每周一次的致癌剂二乙基亚硝胺(DEN)注射 16 周的大鼠发生肝癌。使用这种体内模型,我们评估了 Ras 抑制的肿瘤预防作用与下游信号通路、细胞增殖、细胞周期事件和血管生成的关系。使用 Western blot、定量 PCR、免疫组织化学和转录因子活性测定进行评估。FTS 处理可阻断 DEN 诱导的 NFkB 和 Stat3 的激活。FTS 处理对 DEN 诱导的 TNFα、白细胞介素 6 和 TLR4 的升高没有影响,已知这些转录因子的激活剂。FTS 显著降低了 MAPkinase p38 和 p70S6 激酶的磷酸化,后者是 mTor 激活的替代标志物,而不影响 ERK 和 AKT 的磷酸化。这些事件与转化的 GSTp 阳性肝细胞中 c-myc 和细胞周期蛋白 D 表达的降低以及细胞增殖的减少有关。此外,FTS 处理将细胞增殖从转化的肝细胞转移到明显正常的、GSTp 阴性的肝细胞。FTS 处理并没有下调血管生成标志物 HIFα、VEGF、VEGF 受体 1 和胎盘生长因子的表达。FTS 处理抑制了细胞增殖所涉及的重要信号通路,从而导致转化的肝细胞增殖明显减少,而不影响正常的肝细胞。这种增殖平衡的调整可能有助于 FTS 在 Ras 抑制的情况下在肝癌发生中的肿瘤预防作用。